Gene expression markers for prediction of response to phosphoinositide 3-kinase inhibitors
AssigneeGenomic Health, Inc.
InventorsJoffre B. Baker, Robert J. Pelham, Kevin A. Kwei
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenomic Health, Inc.
InventorsJoffre B. Baker, Robert J. Pelham, Kevin A. Kwei
Estimating the term…
The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.
A method for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor, comprising:
(canceled)
The method of claim [[4]] 1, wherein the one or more genes selected from Table 3 is selected from TRIM50C, GALR2, INSL3, LOC389633, GTPBP10, PGRMC1, DNASE1L3, CACNG2, FAM90A1, OGT, FKBP6, GDAP1L1, CHRNB1, NLGN3, ZNF259, DDN, NXF3, MGC35366, TANK, and LOC116123.
The method of, wherein the expression level of the one or more genes selected from Table 2 or Table 3 is a polypeptide level of the one or more genes selected from Table 2 or Table 3.
A method of increasing sensitivity of a tumor cell to a PI3K inhibitor, comprising,
A method of increasing sensitivity of a tumor cell to a PI3K inhibitor, comprising,
Dependencies are inferred from the claim text.